Match!

FDA approvals usher in the post-interferon era in HCV

Published on Jan 1, 2014in Nature Biotechnology
· DOI :10.1038/nbt0114-3
Cormac Sheridan C18
Estimated H-index: 18
Abstract
  • References (4)
  • Citations (19)
📖 Papers frequently viewed together
1,142 Citations
3 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References4
Newest
#1Jennifer J. Kiser (University of Colorado Denver)H-Index: 25
#2Charles Williams Flexner (Johns Hopkins University)H-Index: 46
Two selective inhibitors of the hepatitis C virus (HCV) protease nearly double the cure rates for this infection when combined with peginterferon alfa and ribavirin. These drugs, boceprevir and telaprevir, received regulatory approval in 2011 and are the first direct-acting antiviral agents (DAAs) that selectively target HCV. During 2012, at least 30 additional DAAs were in various stages of clinical development. HCV protease inhibitors, polymerase inhibitors, and NS5A inhibitors (among others) ...
56 CitationsSource
4 CitationsSource
Following approval of hepatitis C virus protease inhibitors Incivek and Victrelis, companies are partnering to devise all-oral combination antiviral regimens without interferon α. But the virus is a long way from vanquished. Ken Garber investigates.
22 CitationsSource
#1Plinio PerroneH-Index: 4
#2G LuoniH-Index: 7
Last. Christopher McGuiganH-Index: 34
view all 15 authors...
We report the application of our phosphoramidate ProTide technology to the ribonucleoside analogue 4‘-azidouridine to generate novel antiviral agents for the inhibition of hepatitis C virus (HCV). 4‘-Azidouridine did not inhibit HCV, although 4‘-azidocytidine was a potent inhibitor of HCV replication under similar assay conditions. However 4‘-azidouridine triphosphate was a potent inhibitor of RNA synthesis by HCV polymerase, raising the question as to whether our phosphoramidate ProTide approac...
108 CitationsSource
Cited By19
Newest
#1Fazal Hadi (University of Cambridge)H-Index: 2
#2Yavuz Kulaberoglu (University of Cambridge)H-Index: 4
Last. Walid T. Khaled (University of Cambridge)H-Index: 11
view all 6 authors...
The Naked Mole-Rat, Hetercephalus glaber, is a mouse-sized subterranean rodent native to East Africa. Research on NMRs is intensifying in an effort to gain leverage from their unusual physiology, long-life span and cancer resistance. Few studies have attempted to explain the reasons behind NMRs cancer resistance, but most prominently Tian et al. reported that NMR cells produce high-molecular weight hyaluronan as a potential cause for the NMR's cancer resistance. Tian et al. have shown that NMR c...
1 CitationsSource
Last. Nikolas HeroldH-Index: 9
view all 4 authors...
: Antimetabolites, in particular nucleobase and nucleoside analogues, are cytotoxic drugs that, starting from the small field of paediatric oncology, in combination with other chemotherapeutics, have revolutionised clinical oncology and transformed cancer into a curable disease. However, even though combination chemotherapy, together with radiation, surgery and immunotherapy, can nowadays cure almost all types of cancer, we still fail to achieve this for a substantial proportion of patients. The...
7 CitationsSource
#1Nitzan AvisarH-Index: 1
#2Yael HellerH-Index: 1
Last. Nachman AshH-Index: 1
view all 9 authors...
Background In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4) were eligible for treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir (OMB/PTV/r + DSV) provided through the four national health plans. As all health plans committed to identifying eligible patie...
1 CitationsSource
The design and development of direct-acting antiviral agents that when used in combination cure chronic hepatitis C virus (HCV) infection after 8–24 weeks of therapy are the result of 20 years of intense drug discovery and development effort. Compounds that interfere with the function of every protein expressed by the virus have been characterized, but only inhibitors of the NS3 protease, the NS5A replication complex protein, and the NS5B RNA-dependent RNA polymerase are of clinical relevance. T...
Source
#1Nicholas B. Jennings (UA: University of Arizona)
#2Howard J Eng (UA: University of Arizona)H-Index: 2
The Patient Protection and Affordable Care Act established health insurance marketplaces to allow consumers to make educated decisions about their health care coverage. During the first open enrollment period in 2013, the federally facilitated marketplace in Pima County, Arizona listed 119 plans, making it one of the most competitive markets in the country. This study compares these plans based on differences in consumer cost sharing, including deductibles, co-pays and premiums. Consumer costs w...
Source
Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted yet.This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014.A Markov ...
2 CitationsSource
The development of direct-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8–12 weeks of daily, well-tolerated therapy has revolutionized the treatment of this insidious disease. In this article, three of Bristol-Myers Squibb’s HCV programs are summarized, each of which produced a clinical candidate: the NS3 protease inhibitor asunaprevir (64), marketed as Sunvepra, the NS5A replication complex inhibitor daclatasvir (117), marketed as Daklinza, and the allo...
16 CitationsSource
#1Clara WeilH-Index: 5
#2Chizoba Nwankwo (MSD: Merck & Co.)H-Index: 6
Last. Varda Shalev (TAU: Tel Aviv University)H-Index: 32
view all 6 authors...
Hepatitis C affects an estimated 130 million people worldwide and is a major cause of chronic liver disease. This retrospective database study aims to describe the epidemiology of HCV-infected patients in Maccabi Healthcare Services, a 2-million-member health maintenance organization in Israel. HCV was identified by cross-linking diagnoses, laboratory data, and dispensed HCV treatment (1993-2013). The point-prevalence of HCV in 2012 and annual incidence of newly-diagnosed HCV during 2003-2012 (i...
6 CitationsSource
#1Sevil Şenkardeş (Marmara University)H-Index: 3
#2Neerja Kaushik-Basu (RU: Rutgers University)H-Index: 17
Last. S. Gueniz Kuecuekguezel (Marmara University)H-Index: 13
view all 7 authors...
Abstract Hepatitis C virus (HCV) infection is a main cause of chronic liver disease, leading to liver cirrhosis and hepatocellular carcinoma (HCC). The objective of our research was to develop effective agents against viral replication. We have previously identified the hydrazide–hydrazone scaffold as a promising hepatitis C virus (HCV) and hepatocelluler inhibitor. Herein we describe the design a number of 2′,4′-difluoro-4-hydroxy- N' -(arylmethylidene) biphenyl-3-carbohydrazide (3a-t) as anti-H...
24 CitationsSource
#1Derek J. Ward (University of Birmingham)H-Index: 8
#2Edward Hammond (University of Birmingham)H-Index: 1
Last. Andrew Stevens (University of Birmingham)H-Index: 30
view all 4 authors...
Objectives Recent decades have witnessed the development of highly innovative new antiviral drug therapies. However, there are concerns that rising costs and lengthening development times could have implications for future patient access to innovative new drugs. We sought to establish whether the time taken for the clinical development of new antiviral drugs launched in the UK had increased since the 1980s. Design and setting Retrospective observational study of all new antiviral drugs licensed ...
2 CitationsSource